No.

 Title

Application number

Authority

Application date

Status

LNT001

Bacteriphage of Pseudomonas aeruginosa and uses thereof

10-1382893

KR

2014.04.01

Granted

LNT002

Bacteriophage of Salmonella enterica and uses thereof

10-1449417

KR

2014.10.02

Granted

LNT003

Composition for infecting bacteria resistant to bacteriophage infection comprising bacteriophage PBECO4 or CEA derived there from and its use

10-1607395

KR

2016.03.23

Granted

LNT004

Bacteriophage of PA7 of Pseudomonas aeruginosa

10-1612607

KR

2016.04.07

Granted

LNT005

Composition and method of increasing production of bacteriophage by use of Reactive oxygen species

10-1909831

KR

2018.10.12

Granted

LNT006

Bacteriophage of Klebsiella pneumoniae and uses thereof 

 10-2019-0022686

KR

2019.02.26

Applied

LNT007 

Bacteriophage of Pseudomonas aeruginosa and uses thereof

 10-2019-0117450

KR

2019.09.24

Applied

LNT008

Novel Polypeptide and Antibiotics against Enterococcus spp. Bacteria Comprising the Polypeptide

10-2224896

KR

2021.03.02 

Granted

LNT009

Novel Polypeptide and Antibiotics against Gram-Negative Bacteria  Comprising the Polypeptide

10-2224897

KR

2021.03.02

Granted

LNT010

Polypeptide Variants and Antibiotics against Gram-Negative Bacteria Comprising the Same

10-2228999

KR

2021.03.11

Granted

LNT011

Fusion Polypeptides and Antibiotics against Gram-Negative Bacteria Comprising the Same 

10-2286544

KR

2021.07.30

Granted

LNT012

Polypeptides, Fusion polypeptide, and Antibiotic against Gram-negative bacteria comprising same

 PCT/KR2021/006302

PCT

2021.05.20 

Disclosed

LNT013

Novel Polypeptides and Antibiotics against Gram-Negative Bacterium Comprising the same

10-2534221

KR

2023.05.15 

Granted

LNT014

Composition and method for increasing production of bacteriophage, using reactive oxygen species 

EP 3677671 A1 

EU

2020.07.08 

Disclosed 

LNT015

Composition and method for increasing production of bacteriophage, using reactive oxygen species 

 US 11,898,171

US

2024.02.13

Granted

LNT016

Novel polypeptides, fusion polypeptide, and antibiotic against Gram-Negative Bacteria comprising same

11807881

US

2023.11.07

Granted

LNT017

Novel  polypeptides, fusion polypeptide, and antibiotic against Gram-Negative bacteria comprising same

 EP 21809334.2

EU

2022.07.14

Disclosed

LNT018

Novel polypeptides and Antibiotics against Gram-Negative Bacterium Comprising the same

PCT/KR2022/012373 

PCT

2022.08.18

Applied

LNT019

Novel polypeptides and Antibiotics against Gram-Negative Bacterium Comprising the same 

US 17/820,316 

US

2022.08.17

Applied

LNT020

Polypeptides and antibiotics against Gram-negative bacterium comprising the same 

202210999482.0 

 CN

2022.08.19

Granted

LNT021

Novel polypeptides and Antibiotics against Gram-Negative Bacterium Comprising the same  

 EP 22191276.9

 EU

2022.08.19 

Applied

LNT022

Novel  polypeptides, fusion polypeptide, and antibiotic against Gram-Negative bacteria comprising same 

 202180018132.5

 CN

2023.02.10

Granted

LNT023

Novel  polypeptides, fusion polypeptide, and antibiotic against Gram-Negative bacteria comprising same 

 202247062244

IN

2022.11.01 

Disclosed

LNT024

Novel  polypeptides, fusion polypeptide, and antibiotic against Gram-Negative bacteria comprising same 

 CA 3184447 

CA

2022.11.21

Disclosed

LNT025

Novel  polypeptides, fusion polypeptide, and antibiotic against Gram-Negative bacteria comprising same 

2022-570284 

JP

2022.11.16

Disclosed